Iovance Biotherapeutics Net Income
| IOVA Stock | USD 2.53 0.17 7.20% |
As of the 7th of February, Iovance Biotherapeutics retains the Downside Deviation of 4.38, risk adjusted performance of 0.0838, and Market Risk Adjusted Performance of 1.07. Iovance Biotherapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Iovance Biotherapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.8604 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -335 M | -318.2 M | |
| Net Loss | -335 M | -318.2 M | |
| Net Loss | -356.3 M | -338.5 M | |
| Net Loss | (1.16) | (1.21) | |
| Net Income Per E B T | 0.89 | 0.79 |
Iovance | Net Income | Build AI portfolio with Iovance Stock |
Analyzing Iovance Biotherapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Iovance Biotherapeutics's current valuation and future prospects.
Latest Iovance Biotherapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Iovance Biotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Iovance Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Iovance Biotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Iovance Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iovance Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (372.18 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Iovance Net Income Regression Statistics
| Arithmetic Mean | (176,261,964) | |
| Coefficient Of Variation | (91.00) | |
| Mean Deviation | 143,962,932 | |
| Median | (123,580,000) | |
| Standard Deviation | 160,397,011 | |
| Sample Variance | 25727.2T | |
| Range | 444M | |
| R-Value | (0.92) | |
| Mean Square Error | 4159.3T | |
| R-Squared | 0.85 | |
| Slope | (29,257,360) | |
| Total Sum of Squares | 411635.2T |
Iovance Net Income History
Other Fundumenentals of Iovance Biotherapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Iovance Biotherapeutics Net Income component correlations
Iovance Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Iovance Biotherapeutics is extremely important. It helps to project a fair market value of Iovance Stock properly, considering its historical fundamentals such as Net Income. Since Iovance Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iovance Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iovance Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. Market participants price Iovance higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Iovance Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth 0.152 | Return On Assets | Return On Equity |
Understanding Iovance Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Iovance's accounting equity. The concept of intrinsic value - what Iovance Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Iovance Biotherapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iovance Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Iovance Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Iovance Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Iovance Biotherapeutics.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Iovance Biotherapeutics on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Iovance Biotherapeutics or generate 0.0% return on investment in Iovance Biotherapeutics over 90 days. Iovance Biotherapeutics is related to or competes with Ginkgo Bioworks, MBX Biosciences, Erasca, Replimune, MeiraGTx Holdings, MoonLake Immunotherapeuti, and Vir Biotechnology. Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer ... More
Iovance Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Iovance Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Iovance Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.38 | |||
| Information Ratio | 0.0785 | |||
| Maximum Drawdown | 37.34 | |||
| Value At Risk | (7.58) | |||
| Potential Upside | 11.81 |
Iovance Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iovance Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Iovance Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Iovance Biotherapeutics historical prices to predict the future Iovance Biotherapeutics' volatility.| Risk Adjusted Performance | 0.0838 | |||
| Jensen Alpha | 0.5155 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.109 | |||
| Treynor Ratio | 1.06 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Iovance Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Iovance Biotherapeutics February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0838 | |||
| Market Risk Adjusted Performance | 1.07 | |||
| Mean Deviation | 4.34 | |||
| Semi Deviation | 4.13 | |||
| Downside Deviation | 4.38 | |||
| Coefficient Of Variation | 1072.37 | |||
| Standard Deviation | 6.08 | |||
| Variance | 37.01 | |||
| Information Ratio | 0.0785 | |||
| Jensen Alpha | 0.5155 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.109 | |||
| Treynor Ratio | 1.06 | |||
| Maximum Drawdown | 37.34 | |||
| Value At Risk | (7.58) | |||
| Potential Upside | 11.81 | |||
| Downside Variance | 19.2 | |||
| Semi Variance | 17.07 | |||
| Expected Short fall | (5.50) | |||
| Skewness | 1.58 | |||
| Kurtosis | 4.99 |
Iovance Biotherapeutics Backtested Returns
Iovance Biotherapeutics appears to be risky, given 3 months investment horizon. Iovance Biotherapeutics holds Efficiency (Sharpe) Ratio of 0.0457, which attests that the entity had a 0.0457 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Iovance Biotherapeutics, which you can use to evaluate the volatility of the firm. Please utilize Iovance Biotherapeutics' Downside Deviation of 4.38, risk adjusted performance of 0.0838, and Market Risk Adjusted Performance of 1.07 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Iovance Biotherapeutics holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 0.52, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iovance Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Iovance Biotherapeutics is expected to be smaller as well. Please check Iovance Biotherapeutics' expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Iovance Biotherapeutics' current trending patterns will revert.
Auto-correlation | -0.03 |
Very weak reverse predictability
Iovance Biotherapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Iovance Biotherapeutics time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Iovance Biotherapeutics price movement. The serial correlation of -0.03 indicates that only 3.0% of current Iovance Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.03 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Iovance Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Iovance Biotherapeutics reported net income of (372.18 Million). This is 209.05% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 165.18% higher than that of the company.
Iovance Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iovance Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iovance Biotherapeutics could also be used in its relative valuation, which is a method of valuing Iovance Biotherapeutics by comparing valuation metrics of similar companies.Iovance Biotherapeutics is currently under evaluation in net income category among its peers.
Iovance Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iovance Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iovance Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Iovance Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Iovance Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Iovance Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iovance Biotherapeutics' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 4.6 M | Principal Financial Group Inc | 2025-06-30 | 4.6 M | Citadel Advisors Llc | 2025-06-30 | 4.1 M | Bank Of America Corp | 2025-06-30 | 4 M | Palo Alto Investors, Llc | 2025-06-30 | 3.4 M | Soleus Capital Management, L.p. | 2025-06-30 | 3.3 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 2.9 M | Royal Bank Of Canada | 2025-06-30 | 2.4 M | Orion Investment Co | 2025-06-30 | 2.3 M | Mhr Fund Management Llc | 2025-06-30 | 29 M | Vanguard Group Inc | 2025-06-30 | 25.1 M |
Iovance Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.59) % | ||||
| Operating Margin | (1.33) % | ||||
| Current Valuation | 716.32 M | ||||
| Shares Outstanding | 396.97 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 61.85 % | ||||
| Number Of Shares Shorted | 117.1 M | ||||
| Price To Earning | (3.51) X | ||||
| Price To Book | 1.37 X | ||||
| Price To Sales | 3.74 X | ||||
| Revenue | 164.07 M | ||||
| Gross Profit | 51.82 M | ||||
| EBITDA | (351.67 M) | ||||
| Net Income | (372.18 M) | ||||
| Cash And Equivalents | 424.46 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 58.26 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (352.98 M) | ||||
| Short Ratio | 9.38 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 9.11 | ||||
| Number Of Employees | 838 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 936.84 M | ||||
| Total Asset | 910.43 M | ||||
| Retained Earnings | (2.38 B) | ||||
| Working Capital | 334.68 M | ||||
| Current Asset | 290.82 M | ||||
| Current Liabilities | 10.12 M | ||||
| Net Asset | 910.43 M |
About Iovance Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iovance Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iovance Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iovance Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. Market participants price Iovance higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Iovance Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth 0.152 | Return On Assets | Return On Equity |
Understanding Iovance Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Iovance's accounting equity. The concept of intrinsic value - what Iovance Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Iovance Biotherapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iovance Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.